[go: up one dir, main page]

AR077297A1 - Medicamento para uso prolongado de nsaid - Google Patents

Medicamento para uso prolongado de nsaid

Info

Publication number
AR077297A1
AR077297A1 ARP100102334A ARP100102334A AR077297A1 AR 077297 A1 AR077297 A1 AR 077297A1 AR P100102334 A ARP100102334 A AR P100102334A AR P100102334 A ARP100102334 A AR P100102334A AR 077297 A1 AR077297 A1 AR 077297A1
Authority
AR
Argentina
Prior art keywords
nsaid
cobisprotone
pharmaceutically acceptable
acid
patient
Prior art date
Application number
ARP100102334A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR077297A1 publication Critical patent/AR077297A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee un medicamento que comprende cobisprotona o su sal, éster, éter o amida farmacéuticamente aceptable para el tratamiento prolongado de una enfermedad o condicion patologica que es una de las indicaciones para el uso de NSAID en un paciente humano, en donde la cobisprotona se administra en al menos 36 mcg por día al paciente que recibe un NSAID. Al administrar cobisprotona o su sal, éster, éter o amida farmacéuticamente aceptable en combinacion con un NSAID, el paciente puede recibir el NSAID durante un período prolongado. Reivindicacion 5: El uso de acuerdo con la reivindicacion 1, en donde la NSAID está seleccionada del grupo que consiste en salicilatos, indometacina, flurbiprofeno, diclofenac, ketorolac, naproxeno, piroxicam, tebufelona, ibuprofeno, etodolac, nabumetona, tenidap, alcofenac, antipirina, aminopirina, dipirona, aminopirona, fenilbutazona, clofezona, oxifenbutazona, prenazona, apazona, benzidamina, bucolome, cincofeno, clonixina, ditrazol, epirizol, fenoprofeno, floctafenina, ácido flufenámico, glafenina, indoprofeno, ketoprofeno, loxoprofeno, ácido meclofenámico, ácido mefenámico, ácido niflumico, fenacetina, salidifamidas, sulindac, suprofeno, tolmetina, una de sus sales farmacéuticamente aceptables y una mezcla de ellos.
ARP100102334A 2009-06-30 2010-06-30 Medicamento para uso prolongado de nsaid AR077297A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22169809P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
AR077297A1 true AR077297A1 (es) 2011-08-17

Family

ID=43411168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102334A AR077297A1 (es) 2009-06-30 2010-06-30 Medicamento para uso prolongado de nsaid

Country Status (15)

Country Link
US (1) US20110034424A1 (es)
EP (1) EP2448573A4 (es)
KR (1) KR20120099366A (es)
CN (1) CN102470122A (es)
AR (1) AR077297A1 (es)
AU (1) AU2010267000A1 (es)
BR (1) BRPI1015919A2 (es)
CA (1) CA2765453A1 (es)
IL (1) IL216858A0 (es)
MX (1) MX2012000058A (es)
NZ (1) NZ597675A (es)
RU (1) RU2012102980A (es)
TW (1) TW201105329A (es)
WO (1) WO2011002100A1 (es)
ZA (1) ZA201200656B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013161973A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1041012A (en) * 1973-07-10 1978-10-24 American Home Products Corporation Method of reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammotory drugs and compositions therefor
US3917828A (en) * 1974-01-28 1975-11-04 Upjohn Co Method of reducing the undesirable gastraintestinal effects of prostaglandin synthetase inhibitors
US5225439A (en) * 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5380709A (en) * 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
PT1426361E (pt) * 1999-10-15 2008-10-08 Sucampo Ag Nova composição contendo um composto bicíclico e um glicérido
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
US8962688B2 (en) * 2005-04-12 2015-02-24 Sucampo Ag Method for the treatment of gastrointestinal disorders
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Also Published As

Publication number Publication date
EP2448573A4 (en) 2012-11-28
BRPI1015919A2 (pt) 2016-04-26
CA2765453A1 (en) 2011-01-06
NZ597675A (en) 2014-07-25
MX2012000058A (es) 2012-01-27
EP2448573A1 (en) 2012-05-09
IL216858A0 (en) 2012-02-29
CN102470122A (zh) 2012-05-23
WO2011002100A1 (en) 2011-01-06
TW201105329A (en) 2011-02-16
ZA201200656B (en) 2012-10-31
US20110034424A1 (en) 2011-02-10
AU2010267000A1 (en) 2012-02-09
RU2012102980A (ru) 2013-08-10
KR20120099366A (ko) 2012-09-10

Similar Documents

Publication Publication Date Title
ES2541528T3 (es) Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
NZ582327A (en) Pharmaceutical combination of nsaid and prostaglandin compound
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
JP2010532314A5 (es)
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
AR077297A1 (es) Medicamento para uso prolongado de nsaid
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
RU2016148183A (ru) (s)-пирлиндол и его фармацевтические приемлемые соли для применения в медицине
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
RU2016148182A (ru) (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
GT200600263A (es) Regimen de dosificacion para prasugrel
DOP2012000280A (es) Combinación de un aine y un aminoacido
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
AR069548A1 (es) Sales de propionato de 3-(2,2,2- trimetilhidrazinio ) en el tratamiento de la enfermedad cardiaca isquemica y uso medico
BR112021026291A2 (pt) Lemborexant para tratar problemas de sono
Homa Ilkhani Effect of intravenous ketorolac on postoperative pain in mandibular fracture surgery; a randomized, double-blind, placebo-controlled trial
LIU et al. Treatment options for patients with recurrent Graves hyperthyroidism after anti-thyroid drug treatment
闫潇 Interleukin-17 in gingival tissue and serum in ovariectomized mice
CY1120970T1 (el) Φαρμακευτικη μορφη δοσολογιας που περιλαμβανει 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4',9'-διυδρο-3ή-σπeipo[kykλoeξano-1,1'-πυρano[3,4,b]inδoλ]-4-aminh για την αγωγη του αλγαισθητικου πονου
Mueen Ullah et al. Preload Versus Coload and Vasopressor requirement for the prevention of spinal anesthesia induced hypotension in non-obstetric patients

Legal Events

Date Code Title Description
FB Suspension of granting procedure